Apellis Pharmaceuticals (APLS) Financials

Apellis Pharmaceuticals Inc (APLS) is a biopharmaceutical company that develops and commercializes therapies for patients with complement-mediated diseases. The company's primary focus is on the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA). PNH is a rare, life-threatening blood disorder characterized by the destruction of red blood cells. GA is an advanced form of age-related macular degeneration (AMD) that leads to progressive loss of vision. Apellis Pharmaceuticals' innovative approach involves targeting the complement cascade, a part of the immune system responsible for inflammation and cell destruction.

The income statement is a financial statement that shows a company's revenue, expenses, and net income or loss over a specific period. For Apellis Pharmaceuticals Inc (APLS), the income statement provides key information about the company's financial performance. It reveals the total revenue generated by the company during the period, as well as the expenses incurred to generate that revenue. The difference between the revenue and expenses is the company's net income. The income statement also provides details about the company's gross profit, EBIT (earnings before interest and taxes), and EBITDA (earnings before interest, taxes, depreciation, and amortization). These metrics help investors assess the company's profitability and financial health.